Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.55 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3420311 | 0.90 | NPC1 (0.59) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL2394596 | 0.84 | NPC1 (0.61) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL3419853 | 0.84 | GAA (0.55) | KMT2ARAB9AADORA3HTTJAK2 | |
| SCHEMBL3418472 | 0.84 | RXFP1 (0.57) | KMT2AMEN1CCNA2CDK2CCNA1 | |
| SCHEMBL7164136 | 0.83 | RAB9A (0.53) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL3937976 | 0.83 | CCNA2 (0.57) | KMT2AMEN1CCNA2CDK2CCNA1 | |
| SCHEMBL3419889 | 0.83 | HTT (0.45) | KMT2AMEN1CCNA2CDK2CCNA1 | |
| SCHEMBL7157005 | 0.83 | NPC1 (0.51) | KMT2AMEN1NPC1RAB9AF2 | |
| SCHEMBL14082183 | 0.83 | TRPV1 (0.55) | KMT2AMEN1NPC1RAB9AF2 | |
| SCHEMBL4535243 | 0.82 | LMNA (0.58) | KMT2AHDAC6HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214197-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2023-07-26 | — | — | EP | claimed |
| WO-2020198053-A1 | 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-01 | — | — | WO | claimed |
| WO-2015193229-A1 | BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | claimed |
| EP-2925322-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2015-10-07 | — | — | EP | claimed |
| WO-2014085210-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-06-05 | — | — | WO | claimed |
| JP-4555547-B2 | — | — | 2010-10-06 | — | — | JP | claimed |
| CN-101595104-A | New crystalline compound as the GLK activator | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | CN | claimed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | claimed |
| JP-2004505977-A | — | — | 2004-02-26 | — | — | JP | claimed |
| EP-1320531-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2003-06-25 | — | — | EP | claimed |
| WO-2002012242-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2002-02-14 | — | — | WO | claimed |
| US-6118008-A | FIBER-REACTIVE DYE; HAIR DYE | L'OREAL (FR) | 2000-09-12 | — | — | US | claimed |
| EP-0900206-A1 | NEW DIAMINO PYRAZOLS, THEIR SYNTHESIS, KERATIN FIBRE DYEING COMPOSITIONS CONTAINING THEM, KERATIN FIBRE DYEING METHODS | L'OREAL (FR) | 1999-03-10 | — | — | EP | claimed |
| WO-1997042173-A1 | NEW DIAMINO PYRAZOLS, THEIR SYNTHESIS, KERATIN FIBRE DYEING COMPOSITIONS CONTAINING THEM, KERATIN FIBRE DYEING METHODS | L'OREAL (FR) | 1997-11-13 | — | — | WO | claimed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| EP-0900206-A1 | NEW DIAMINO PYRAZOLS, THEIR SYNTHESIS, KERATIN FIBRE DYEING COMPOSITIONS CONTAINING THEM, KERATIN FIBRE DYEING METHODS | L'OREAL (FR) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997042173-A1 | NEW DIAMINO PYRAZOLS, THEIR SYNTHESIS, KERATIN FIBRE DYEING COMPOSITIONS CONTAINING THEM, KERATIN FIBRE DYEING METHODS | L'OREAL (FR) | 1997-11-13 | — | — | WO | disclosed |
| US-5464860-A | Antiepileptic agents | NOVAPHARME (FR) | 1995-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KMT2A 1644/4885MEN1 407/4885CCNA2 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.